IL6 and rheumatoid arthritis: Our understanding of RA pathogenesis has improved, and therapeutic strategies against RA have been revolutionized by the development of targeted drugs such as tumor necrosis factor inhibitors, interleukin-6 (IL-6) blockers, B-cell depletion agents, and inhibitors of T-cell costimulation and Janus kinases5.